A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.